LEADER 02890nam  2200577 a 450 
001 9910141533103321
005 20200520144314.0
010   $a1-118-51132-8
010   $a1-283-91742-4
010   $a1-118-51129-8
035   $a(CKB)2670000000316481
035   $a(EBL)1104475
035   $a(OCoLC)823389919
035   $a(SSID)ssj0000803906
035   $a(PQKBManifestationID)11439408
035   $a(PQKBTitleCode)TC0000803906
035   $a(PQKBWorkID)10812513
035   $a(PQKB)10902097
035   $a(OCoLC)831464032
035   $a(MiAaPQ)EBC1104475
035   $a(Au-PeEL)EBL1104475
035   $a(CaPaEBR)ebr10641813
035   $a(CaONFJC)MIL422992
035   $a(PPN)178874922
035   $a(EXLCZ)992670000000316481
100   $a20121010d2013      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aDevalued and distrusted$b[electronic resource] $ecan the pharmaceutical industry restore its broken image? /$fJohn L. LaMattina
210   $aHoboken, N.J. $cWiley$d2013
215   $a1 online resource (137 p.)
300   $aDescription based upon print version of record.
311   $a1-118-48747-8 
320   $aIncludes bibliographical references and index.
327   $aMachine generated contents note:  Introduction Part 1. "The 4 Secrets That Drug Companies Don't Want You to Know" Part 2. What Has Happened to R&D Productivity? a. Impact of Mergers b. Impact of FDA c. Impact of Payers Part 3. Challenges in Key Therapeutic Areas for Improving Health a. Cancer b. Diseases of the Brain c. Cardiovascular Disease d. Diabetes e. Bacterial Infections Part 4. Improving R&D Output a. View of Others b. Personal Vision Part 5. Restoring the Pharma Image Part 6. Final Thoughts.
330   $a"While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R&D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"--$cProvided by publisher.
606   $aPharmaceutical industry$xCorrupt practices
615  0$aPharmaceutical industry$xCorrupt practices.
676   $a338.4/76151
686   $aMED071000$2bisacsh
700   $aLaMattina$b John L$0963935
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910141533103321
996   $aDevalued and distrusted$92185978
997   $aUNINA